Contrasting Teleflex (TFX) & AngioDynamics (ANGO)

AngioDynamics (NASDAQ: ANGO) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares AngioDynamics and Teleflex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AngioDynamics 2.00% 5.19% 3.79%
Teleflex 12.36% 16.12% 7.78%

Risk & Volatility

AngioDynamics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Institutional and Insider Ownership

85.8% of AngioDynamics shares are held by institutional investors. Comparatively, 93.0% of Teleflex shares are held by institutional investors. 1.9% of AngioDynamics shares are held by company insiders. Comparatively, 2.4% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares AngioDynamics and Teleflex’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
AngioDynamics $349.64 million 1.72 $51.23 million $0.19 86.11
Teleflex $1.99 billion 4.64 $521.06 million $5.23 39.26

Teleflex has higher revenue and earnings than AngioDynamics. Teleflex is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for AngioDynamics and Teleflex, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AngioDynamics 0 2 3 0 2.60
Teleflex 0 1 5 0 2.83

AngioDynamics presently has a consensus price target of $18.40, indicating a potential upside of 12.47%. Teleflex has a consensus price target of $228.00, indicating a potential upside of 11.04%. Given AngioDynamics’ higher possible upside, research analysts plainly believe AngioDynamics is more favorable than Teleflex.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.7%. AngioDynamics does not pay a dividend. Teleflex pays out 26.0% of its earnings in the form of a dividend.

Summary

Teleflex beats AngioDynamics on 13 of the 16 factors compared between the two stocks.

About AngioDynamics

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company’s products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products, which are offered under Hudson RCI brand. As of December 31, 2016, it manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. Its all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.

What are top analysts saying about AngioDynamics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AngioDynamics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit